BDRX (Biodexa Pharmaceuticals) Beta: 1.7953 (As of Jun. 25, 2026)


BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $2.52
GF Value $2.26
Valuation Modestly Overvalued
View Full Analysis

What is Biodexa Pharmaceuticals Beta?

Biodexa Pharmaceuticals BDRX -3.45% 45 Beta is 1.7953 as of Jun. 25, 2026. GuruFocus rates BDRX with a GF Score™ of 45/100 and a GF Value™ of $2.26 (Modestly Overvalued).

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Biodexa Pharmaceuticals's Beta is 1.7953.


Biodexa Pharmaceuticals  (NAS:BDRX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Biodexa Pharmaceuticals Beta Related Terms


Biodexa Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Beta Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.13 2.06 0.80 0.66 0.92

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.63 0.66 1.33 0.92

BDRX vs CASIF, OGEN, ELOX: Beta Comparison

For the Biotechnology subindustry, Biodexa Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biodexa Pharmaceuticals Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biodexa Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Biodexa Pharmaceuticals's Beta falls into.


BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.7953 mean?
Biodexa Pharmaceuticals (BDRX) has a Beta of 1.7953 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Beta too high?
Biodexa Pharmaceuticals' current Beta is 1.7953. Overall, Biodexa Pharmaceuticals has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Beta compare to CASIF and OGEN?
Biodexa Pharmaceuticals' Beta of 1.7953 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Beta is 1.7953. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biodexa Pharmaceuticals (BDRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.26, compared to a current price of $2.52 — trading 11.5% above its estimated fair value. The current Beta is 1.7953. Biodexa Pharmaceuticals' overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current Beta is 1.7953 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $2.52 is trading 11.5% above its estimated GF Value™ of $2.26. GuruFocus considers Biodexa Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for BDRX:

  • Beta: 1.7953
  • GF Value™: $2.26 vs. price of $2.52 (11.5% above fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.52
Price
$2.26
GF Value